Remember past spring when magnetic ferritin in Covid bioweapons was a conspiracy theory and we were getting our YouTube channels and socials wiped out for exposing it? That was fun*!
The spike ferritin nanoparticle (SpFN) vaccine was designed as a ferritin-fusion recombinant protein for expression as a nanoparticle, and has been described in detail previously (20). Briefly, the spike protein sequence was derived from the Wuhan-Hu-1 genome sequence (GenBank accession number: MN908947.3)
Ferritin sounds familiar? No doubt.
US PATENT FOR FERRITIN NANOPARTICLE COMPOSITIONS AND METHODS TO MODULATE CELL ACTIVITY PATENT (PATENT # 10,786,570)
Ferritin nanoparticle compositions and methods to modulate cell activity
Jul 30, 2018 – The Rockefeller University
The present invention provides methods and compositions for the remote control of cell function based on the use of radiofrequency waves to excite nanoparticles targeted to specific cell types. The nanoparticles may be applied to the target cell extracellularly and/or expressed intracellularly. The cell type of interest expresses a temperature sensitive channel wherein excitation of the nanoparticles results in a localized temperature increase that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject. Accordingly, the invention provides a generic approach for treatment of any disease associated with a protein deficiency. – SOURCE
And, coincidentally, of course:
In patients with severe COVID-19 disease, decreased hemoglobin along with elevated erythrocyte sedimentation rate (ESR), C-reactive protein, lactate dehydrogenase, albumin , serum ferritin , and low oxygen saturation  provide additional support for this hypothesis.
SPIKES AND NANOPARTICLES
“The spike protein from SARS-CoV-2 is quite large, so scientists often formulate abridged versions that are simpler to make and easier to use. After closely examining the spike, Kim and his team chose to remove a section near the bottom.
To complete their vaccine, they combined this shortened spike with nanoparticles of ferritin – an iron-containing protein – which has been previously tested in humans. Before the pandemic, Powell had been working with these nanoparticles to develop an Ebola vaccine. Together with scientists at the SLAC National Accelerator Laboratory, the researchers used cryo-electron microscopy to get a 3D image of the spike ferritin nanoparticles in order to confirm that they had the proper structure.
For the mouse tests, the researchers compared their shortened spike nanoparticles to four other potentially useful variations: nanoparticles with full spikes, full spikes or partial spikes without nanoparticles, and a vaccine containing just the section of the spike that binds to cells during infection. Testing the effectiveness of these vaccines against actual SARS-CoV-2 virus would have required the work to be done in a Biosafety Level 3 lab, so the researchers instead used a safer pseudo-coronavirus that was modified to carry SARS-CoV-2’s spikes.”
So they took a code from a server, like all the other vaccine makers (see link above), they took a nanoparticle that was ‘illegal’ to discuss on TheirTubes and they did what?
US ARMY CREATES SINGLE VACCINE AGAINST ALL COVID & SARS VARIANTS, RESEARCHERS SAY
WITHIN WEEKS, WALTER REED RESEARCHERS EXPECT TO ANNOUNCE THAT HUMAN TRIALS SHOW SUCCESS AGAINST OMICRON—AND EVEN FUTURE STRAINS.
BY TARA COPP, SENIOR PENTAGON REPORTER, DEFENSE ONE
DECEMBER 21, 2021, Updated on Dec. 22
Within weeks, scientists at the Walter Reed Army Institute of Research expect to announce that they have developed a vaccine that is effective against COVID-19 and all its variants, even Omicron, as well as previous SARS-origin viruses that have killed millions of people worldwide.
The achievement is the result of almost two years of work on the virus. The Army lab received its first DNA sequencing of the COVID-19 virus in early 2020. Very early on, Walter Reed’s infectious diseases branch decided to focus on making a vaccine that would work against not just the existing strain but all of its potential variants as well.
Walter Reed’s Spike Ferritin Nanoparticle COVID-19 vaccine, or SpFN, completed animal trials earlier this year with positive results. Phase 1 of human trials, wrapped up this month, again with positive results that are undergoing final review, Dr. Kayvon Modjarrad, director of Walter Reed’s infectious diseases branch, said in an exclusive interview with Defense One on Tuesday. The new vaccine will still need to undergo phase 2 and phase 3 trials.
“We’re testing our vaccine against all the different variants, including Omicron,” Modjarrad said.
On Wednesday, Walter Reed officials said in a statement that its vaccine “was not tested on the Omicron variant,“ but later clarified in an email to Defense One that while the recently discovered variant was not part of the animal studies, it is being tested in the lab against clinical human trial samples. These “neutralization assays” test whether antibodies can inhibit the growth of a virus.
“We want to wait for those clinical data to be able to kind of make the full public announcements, but so far everything has been moving along exactly as we had hoped,” Modjarrad said.
Unlike existing vaccines, Walter Reed’s SpFN uses a soccer ball-shaped protein with 24 faces for its vaccine, which allows scientists to attach the spikes of multiple coronavirus strains on different faces of the protein.
“It’s very exciting to get to this point for our entire team and I think for the entire Army as well,” Modjarrad said.
THAT MOMENT WHEN US ARMY ANNOUNCES FERRITIN-BASED VACCINES IN DECEMBER, AND MY REPORTS ABOUT IT WERE GETTING DELETED BY LIBTARDTECH LAST SUMMER:
These ferritin nanoparticles are rapidly drained to lymph nodes and target dendritic cells, especially CD8α+ population, upon subcutaneous immunization.
SERIES OF PRECLINICAL STUDIES SUPPORTS THE ARMY’S PAN-CORONAVIRUS VACCINE DEVELOPMENT STRATEGY
Source Army.mil December 16, 2021
SILVER SPRING, Md. – A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by researchers at the Walter Reed Army Institute of Research (WRAIR) not only elicits a potent immune response but may also provide broad protection against SARS-CoV-2 variants of concern as well as other coronaviruses.
Scientists in WRAIR’s Emerging Infectious Diseases Branch (EIDB) developed the SpFN nanoparticle vaccine, based on a ferritin platform, as part of a forward-thinking “pan-SARS” strategy that aims to address the current pandemic and acts as a first line of defense against variants of concern and similar viruses that could emerge in the future.
“The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases,” said Dr. Kayvon Modjarrad, Director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the U.S. Army lead for SpFN. “Our strategy has been to develop a ‘pan-coronavirus’ vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species.”
Pre-clinical studies published today in Science Translational Medicine indicate that the SpFN vaccine protects non-human primates from disease caused by the original strain of SARS-CoV-2 and induces highly-potent and broadly-neutralizing antibody responses against major SARS-CoV-2 variants of concern including the SARS-CoV-1 virus that emerged in 2002.
SpFN entered Phase 1 human trials in April 2021. Early analyses, expected to conclude this month, will provide insights into whether SpFN’s potency and breadth, as demonstrated in preclinical trials, will carry over into humans. The data will also allow researchers to compare SpFN’s immune profile to that of other COVID-19 vaccines already authorized for emergency use.
“This vaccine stands out in the COVID-19 vaccine landscape,” Modjarrad said. “The repetitive and ordered display of the coronavirus spike protein on a multi-faced nanoparticle may stimulate immunity in such a way as to translate into significantly broader protection.”
WRAIR developed a secondary candidate vaccine, a SARS-CoV-2 Spike Receptor-Binding Domain Ferritin Nanoparticle (RFN) vaccine, which targets a smaller part of the coronavirus Spike protein than the SpFN vaccine. Results from a study, published recently in the Proceedings of the National Academy of Sciences, show that this vaccine potentially offers similar protection against an array of SARS-CoV-2 variants and SARS-CoV-1.
“The RFN vaccine candidate is more compact and has some natural advantages as we try to increase the immune response against multiple coronaviruses using a single vaccine platform, so it is still under consideration as part of our pan-coronavirus vaccine development pipeline,” said WRAIR structural biologist and vaccine co-inventor, Dr. Gordon Joyce.
“The threat from COVID-19 continues as it evolves, and eventually there will be other emerging disease threats,” said Dr. Nelson Michael, Director of the Center for Infectious Diseases Research at WRAIR. “Our investment in developing a next generation vaccine is an important step towards getting ahead of COVID-19 and future disease threats.”
A SARS-CoV-2 Ferritin Nanoparticle Vaccine Elicits Protective Immune Responses in Nonhuman Primates
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults
Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/NCT04784767
WELL, GUESS WHAT?
We’ve already published some of that literature past spring..
With what occasion?
Everything will become round again if you (re)visit this pivotal moment in independent journalism that will keep rocking the official narrative:
Those poor people sticking forks and cellphones on their foreheads seem to be the lab rats for this new escalation in the Fourth Industrial Revolution by the World Psychopaths Forum.
And if you want an even larger context, what better evidence that Pharmafia, Big Tech and the Military are not separate entities, they’re rather arms of a common enterprise I like to call “The Military BioTech Complex”.
If you can steal a few moments of peace and warmth with the dearest ones, take good advantage, for me too, I can’t, and these may be our last days before the war on us escalates from psychological and biochemical to kinetic. Then arm up to hold your positions and make it through the Darkest Winter!